Position in NVS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$2,089,234
+$342,385 QoQ
Shares Held
13,331
+16.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#415
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Savvy Advisors, Inc. holds $76,177,926 across 13 Drug Manufacturers - General names. NVS ranks #7 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
21,784 | $26,128,385 | |
| 2 | ABBV |
AbbVie Inc.
|
60,465 | $15,215,412 | |
| 3 | JNJ |
Johnson & Johnson
|
51,624 | $13,110,947 | |
| 4 | MRK |
Merck & Co., Inc.
|
46,232 | $5,940,812 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
64,644 | $3,724,787 | |
| 6 | AMGN |
Amgen Inc
|
8,866 | $3,210,555 | |
| 7 | NVS |
Novartis AG
This page
|
13,331 | $2,089,234 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
15,259 | $1,927,822 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,089,234 | 13,331 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $1,746,849 | 11,436 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,594,742 | 11,567 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $1,290,992 | 10,067 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $1,128,781 | 9,328 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $867,425 | 7,781 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $700,729 | 7,201 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||